Sarah Dunn - Publications

Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid.

Journal: BMJ open

Published: March 11, 2026

Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study.

Journal: Health technology assessment (Winchester, England)

Published: March 03, 2026

A cell line development vector strategy for improved expression of a trispecific T-cell engager in CHO.

Journal: mAbs

Published: February 26, 2026

Carbon footprint of a sample of clinical trials for people with neurological disorders: cross-sectional analysis.

Journal: BMJ open

Published: June 17, 2025

Cost-effectiveness of lifelong eculizumab versus disease monitoring of aHUS.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: April 30, 2025

Next-generation sequencing: A powerful multi-purpose tool in cell line development for biologics production.

Journal: Computational and structural biotechnology journal

Published: December 09, 2024

Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial.

Journal: The Lancet regional health. Europe

Published: October 08, 2024

Interplay of heavy chain introns influences efficient transcript splicing and affects product quality of recombinant biotherapeutic antibodies from CHO cells.

Journal: mAbs

Published: August 09, 2023

CHO synthetic promoters improve expression and product quality of biotherapeutic proteins.

Journal: Biotechnology progress

Published: December 13, 2022

Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm study.

Journal: BMJ open

Published: September 19, 2022

Introduction of a Management Toolkit for Lewy Body Dementia: A Pilot Cluster-Randomized Trial.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: May 19, 2020

Telomerase Activation to Reverse Immunosenescence in Elderly Patients With Acute Coronary Syndrome: Protocol for a Randomized Pilot Trial.

Journal: JMIR research protocols

Published: April 18, 2020

‌

Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid.

Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid.

Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study.

Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study.

A cell line development vector strategy for improved expression of a trispecific T-cell engager in CHO.

A cell line development vector strategy for improved expression of a trispecific T-cell engager in CHO.

Carbon footprint of a sample of clinical trials for people with neurological disorders: cross-sectional analysis.

Carbon footprint of a sample of clinical trials for people with neurological disorders: cross-sectional analysis.

Cost-effectiveness of lifelong eculizumab versus disease monitoring of aHUS.

Cost-effectiveness of lifelong eculizumab versus disease monitoring of aHUS.

Next-generation sequencing: A powerful multi-purpose tool in cell line development for biologics production.

Next-generation sequencing: A powerful multi-purpose tool in cell line development for biologics production.

Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial.

Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial.

Interplay of heavy chain introns influences efficient transcript splicing and affects product quality of recombinant biotherapeutic antibodies from CHO cells.

Interplay of heavy chain introns influences efficient transcript splicing and affects product quality of recombinant biotherapeutic antibodies from CHO cells.

CHO synthetic promoters improve expression and product quality of biotherapeutic proteins.

CHO synthetic promoters improve expression and product quality of biotherapeutic proteins.

Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm study.

Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm study.

Introduction of a Management Toolkit for Lewy Body Dementia: A Pilot Cluster-Randomized Trial.

Introduction of a Management Toolkit for Lewy Body Dementia: A Pilot Cluster-Randomized Trial.

Telomerase Activation to Reverse Immunosenescence in Elderly Patients With Acute Coronary Syndrome: Protocol for a Randomized Pilot Trial.

Telomerase Activation to Reverse Immunosenescence in Elderly Patients With Acute Coronary Syndrome: Protocol for a Randomized Pilot Trial.